Abbisko Therapeutics shares fell after the company said it has struck a strategic collaboration with AstraZeneca to develop a new combination therapy for non-small cell lung cancer. Abbisko will work with AstraZeneca to evaluate Lumipodlin, its oral PD-L1 inhibitor, together with AstraZeneca’s third-generation EGFR-TKI osimertinib in an early-stage clinical program targeting patients with EGFR-mutated and PD-L1 positive tumors.
The news comes after Abbisko said the investigational new drug (IND) application for the combination study was cleared by China’s National Medical Products Administration (NMPA), setting the stage for the planned Phase I/II trial. Abbisko led the Phase II portion of the study, with both companies sharing execution responsibilities.
Key takeaways
- Price move: Abbisko Therapeutics shares were down 3.04% in Wednesday trading, closing at $183.86.
- Catalyst: The company reported NMPA clearance for the IND covering a multicenter Phase I/II study of Lumipodlin plus osimertinib.
- Trial focus: The study will evaluate safety and efficacy in EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC.
- Role in development: Abbisko will lead the Phase II work while AstraZeneca will share trial execution responsibilities.
- Implication: The collaboration targets a segment where current EGFR therapy may be less effective, potentially strengthening both firms’ lung cancer pipelines.
What drove the move
Abbisko Therapeutics said it entered into a strategic collaboration with AstraZeneca to jointly advance a novel IO-TKI combination approach for non-small cell lung cancer. Under the deal, Abbisko’s Lumipodlin—an orally available, selective small-molecule PD-L1 inhibitor—will be tested alongside AstraZeneca’s osimertinib, marketed as TAGRISSO.
The companies plan a multicenter, open-label Phase I/II trial designed to assess safety and efficacy. Enrollment will focus on patients with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC, reflecting the clinical aim of combining targeted EGFR inhibition with checkpoint pathway modulation.
Abbisko added that on May 20, 2026, the IND application for the combination study received clearance from the NMPA in China. The program is structured with Abbisko leading the Phase II portion, while both companies share responsibilities for trial execution.
How the therapy is intended to work
According to Abbisko, Lumipodlin is designed to bind to the PD-L1 receptor and trigger its internalization. By doing so, the therapy aims to inhibit the PD-1/PD-L1 interaction and reduce suppression of T-cell activation. The company said that in preclinical models, Lumipodlin showed anti-tumor activity comparable to approved PD-L1 antibody therapies.
The combination rationale centers on pairing this PD-L1 inhibition strategy with third-generation EGFR-TKI therapy. Abbisko noted that third-generation EGFR-TKIs such as TAGRISSO are the front-line standard of care for patients with EGFR-mutated NSCLC, but it is seeking to address an important limitation: patients with EGFR mutations and high PD-L1 expression have historically shown less benefit from EGFR-TKIs alone.
Market reaction and what investors may watch
Abbisko’s shares fell 3.04% to $183.86 following the announcement, despite the program moving forward with NMPA IND clearance. The early-stage nature of the trial means investors will likely focus less on near-term financial impact and more on how the clinical data progresses—particularly around safety tolerability and signals of efficacy in the targeted subpopulation.
For the combination strategy to gain traction, market participants may look for clear evidence that adding PD-L1 blockade to osimertinib can improve outcomes in EGFR-mutated, PD-L1 positive patients. Given that the trial is Phase I/II and open-label, investors will also be monitoring how quickly the companies can enroll and report interim results, as well as whether the regimen produces manageable safety findings.
Bigger picture for lung cancer development
Abbisko said the collaboration highlights its commitment to advancing oncology therapies and strengthens AstraZeneca’s lung cancer pipeline. The deal also underscores broader industry efforts to refine checkpoint and targeted-therapy sequencing for biomarker-defined groups rather than treating NSCLC populations as uniform.
The companies’ approach focuses on a niche where treatment performance remains a challenge—patients with EGFR mutations and higher PD-L1 expression. If the early results support the hypothesis that the combination can overcome reduced EGFR-TKI benefit, the program could open a pathway toward a more differentiated option for this subgroup.
Abbisko’s stock has traded in a wide range over the past year, with a low of $137.22 and a high of $212.71. With Wednesday’s drop, the shares closed below the mid-point of that range, suggesting investors are weighing the progression of clinical development against uncertainty inherent in early-stage oncology programs.
Looking ahead, investors will likely watch for further trial updates from the Phase I/II study, including enrollment progress, safety outcomes, and early efficacy readouts. Additional catalysts may include upcoming clinical milestones tied to IND progression, and, more broadly for the sector, investor attention will remain on oncology development timelines and regulatory updates as companies advance biomarker-driven combinations.
